Dr. Reddy's Laboratories has announced plans to relocate its North America headquarters and establish a R&D facility in Princeton, New Jersey.
Dr. Reddy’s Laboratories announced plans to relocate its North America headquarters and establish a R&D facility in Princeton, New Jersey, according to an Apr. 9, 2013, press release. Dr. Reddy’s, represented by Jones Lang LaSalle, has entered into two lease agreements for a 75,500-ft2 office facility and a 31,000-ft2 office/laboratory at 107 College Road East and 303 College Road East, respectively, with National Business Parks.
The company anticipates relocation to the office facility at 107 College Road East by the end of the summer of 2013 after the completion of renovations. The new North America headquarters will house the company’s generics, biologics, PSAI, and proprietary product divisions, as well as the corporate support functions within North America. It is projected to employ 300+ employees.
The laboratory facility located at 303 College Road East will undergo a redesign to accommodate Dr. Reddy’s product development and analytical laboratory requirements. Approximately 20,000 ft2 of space will be part of the initial phase of redesign. The laboratory is also expected to be completed by late summer to early fall of 2013, and will employ 35 scientists, chemists, and support personnel.
“The relocation will allow Dr. Reddy's to tap into local talent which will be instrumental in our long term growth,” said G V Prasad, Chairman and CEO, Dr. Reddy’s. “This R&D center, along with centers in Cambridge (UK) and Leiden (Netherlands) establishes our presence within some of the leading innovation centers of the world."
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
FDA Approves Novartis Oral Treatment for Adults with C3 Glomerulopathy
March 25th 2025Fabhalta (iptacopan) received a positive opinion for treatment of C3G from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and has been approved twice before by FDA.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.